Pioneering CAR T-Cell Therapy for Advanced Gastric Cancer

CAR T-Cell Therapy has reached a historic milestone with the approval of satri-cel, the world’s first authorized CAR T treatment for any solid tumor. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at least two prior lines, directly confronting the high incidence, late diagnosis, and limited options that define this aggressive disease.

Precision Targeting Overcomes Microenvironment Barriers

Developed by CARsgen, the therapy uses autologous T cells engineered with a humanized anti-Claudin18.2 single-chain variable fragment, CD8α hinge, CD28 co-stimulatory domain, and CD3ζ signaling element. A proprietary preconditioning regimen incorporating low-dose nab-paclitaxel with standard lymphodepletion was designed to improve CAR T-Cell Therapy infiltration and persistence within the immunosuppressive solid-tumor microenvironment.

Strong Efficacy in Heavily Pretreated Patients

In a randomized phase 2 trial, satri-cel delivered statistically significant survival gains and a manageable safety profile compared with physician’s choice in later-line Claudin18.2-positive gastric cancer. These results validate Claudin18.2 as a clinically relevant target and confirm that optimized delivery can materially extend the reach of CAR T-Cell Therapy beyond blood cancers.

Value Implications for High-Burden Regions

As a one-time autologous therapy capable of reducing repeated hospitalizations, satri-cel offers important quality-of-life and resource-utilization benefits for health economic assessments in Asia, where gastric cancer incidence remains highest. Ongoing trials in earlier lines and additional Claudin18.2-expressing tumors will require robust real-world evidence to support pricing, reimbursement, and broader adoption of this new class of cellular therapy.